Lilly Bio-Medicines splits into neuroscience, immunology units

By The Science Advisory Board staff writers

August 17, 2021 -- Eli Lilly has divided Lilly Bio-Medicines into neuroscience and immunology business units. The company said the move will help it introduce "breakthrough medicines" to people who need them.

Lilly Neuroscience will be led by Senior Vice President and Lilly Oncology President Anne White. White will be responsible for Lilly's products and phase III portfolio in pain and neurodegeneration, including the potential launch of donanemab for the treatment of Alzheimer's disease, according to the company.

Patrik Jonsson has been tapped as president of Lilly Immunology, managing Lilly's products and phase III portfolio of medicines in dermatology, gastroenterology, and rheumatology, the company said. He will retain his current roles as senior vice president and president of Lilly USA, as well as chief customer officer.

In addition, current Loxo Oncology CEO Jacob Van Naarden has been promoted to senior vice president and CEO of Loxo Oncology at Lilly, as well as president of Lilly Oncology. Van Naarden will unify these organizations and join Lilly's executive committee.

In other executive announcements, Lilly International Senior Vice President and President Alfonso Zulueta will retire from Lilly after more than 30 years of service. Zulueta will be succeeded by Ilya Yuffa, who is currently senior vice president and president of Lilly Bio-Medicines. Yuffa, a nearly 25-year Lilly veteran, will lead Lilly's commercial operations in all markets outside of the U.S., except for Canada.

Lilly to acquire Protomer Technologies for $1B
Eli Lilly will acquire private biotechnology firm Protomer Technologies for an estimated $1 billion.
Lilly, MiNA collaborate on saRNA research
Eli Lilly is teaming up with RNA activation therapeutics firm MiNA Therapeutics on a global research collaboration to develop drug candidates using MiNA's...
U.S. purchases another 100K doses of Lilly COVID-19 antibodies
The U.S. government is purchasing a minimum of 100,000 doses of Eli Lilly's bamlanivimab 700 mg and etesevimab 1,400 mg together, which are neutralizing...
Eli Lilly gets EUA for COVID-19 mAb combo
The U.S. Food and Drug Administration has issued an emergency use authorization (EUA) to Eli Lilly for the combination of the monoclonal antibodies (mAbs)...
Lilly's mAb highly protective against COVID-19 in nursing homes
Eli Lilly's monoclonal antibody (mAb) LY-CoV555 (bamlanivimab) significantly reduced the risk of contracting COVID-19 among residents and staff of long-term...

Copyright © 2021

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter